Physician profile
Peter Mencel
NPI 1609858455
$9,449.01
in general payments reported to CMS, 2019-2025
68 companies · $2,106 in 2025
The $2,106 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,164 · 2020: $861 · 2021: $962 · 2022: $1,298 · 2023: $1,738 · 2024: $1,320 · 2025: $2,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,984 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,984.16 |
| Education | $179.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $887.71 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Novartis Pharmaceuticals Corporation | $640.97 | 2019-2025 | |
| Gilead Sciences, INC. | $542.17 | 2019-2025 | Trodelvy |
| Janssen Biotech, INC. | $495.38 | 2019-2025 | Erleada, Balversa, Darzalex |
| Eisai INC. | $409.72 | 2019-2025 | |
| Lilly USA, LLC | $393.80 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $386.84 | 2019-2023 | Tukysa, Padcev |
| Merck Sharp & Dohme LLC | $367.95 | 2019-2023 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $343.57 | 2019-2025 | Enhertu, Tagrisso |
| Stemline Therapeutics INC. | $330.76 | 2023-2025 | Orserdu |
| Abbvie INC. | $283.21 | 2019-2025 | |
| Genentech USA, INC. | $260.62 | 2019-2023 | Venclexta, Rozlytrek, Tecentriq |
| Epizyme, INC. | $236.55 | 2020-2023 | Tazverik |
| Taiho Oncology, INC. | $234.92 | 2019-2025 | |
| Exelixis INC. | $194.12 | 2021-2025 | Cabometyx |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Mencel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.